Nasdaq 100 are attracting significant attention in today’s market. The nasdaq 100 is set to welcome back Moderna as the company prepares to re-enter this prestigious index following significant share price recovery. This comes after Moderna’s recent success in late-stage trials of its cancer vaccine, which has led to considerable buzz among people closely following the pharmaceutical giant. The inclusion is not anticipated to alter Moderna’s sales or pipeline directly, yet it highlights the company’s regained market prominence. As Moderna replaces Warner Bros. Discovery, the move marks a pivotal moment in its post-2024 trajectory. Meanwhile, Moderna stock remains a key focus for market participants.
Moderna Rejoins Nasdaq 100 After Tumultuous Journey
In a significant development, Moderna is set to re-enter the Nasdaq 100 in 2026 after being dropped from the benchmark back in late 2024. The inclusion comes after a remarkable recovery in its share price, which soared following the announcement of successful late-stage trial results for its cancer vaccine in combination with Merck’s Keytruda this past August.
Strong Performance Drives Moderna’s Comeback
Moderna’s shares have seen a substantial increase, trading at about $204 in the afternoon session, marking a 7% rise from Friday’s closing of $190.01. This surge brings the stock close to its late-September peak of $208.90, placing the company’s market value around $82 billion. This is a notable jump from the 52-week low near $22 last November, marking a more than fivefold increase in 2026.
Nasdaq 100 Inclusion: What It Means for Moderna
The Nasdaq announced on October 1 that Moderna will be included in the Nasdaq 100 index before the market opens on October 9, replacing Warner Bros. Discovery. This change follows Warner Bros. Discovery’s merger with Paramount Skydance, which is expected to finalise on October 6. While inclusion in the Nasdaq 100 does not directly affect Moderna’s sales or product pipeline, it often results in index funds purchasing the stock around the effective date.
Valuation Concerns Linger Despite Positive Sentiment
Despite the positive momentum, there are ongoing concerns about Moderna’s valuation. Citi analyst Geoff Meacham recently downgraded Moderna to Sell, with a price target increase from $60 to $80, citing these valuation concerns. Meacham noted that Moderna’s market cap is now comparable to Regeneron’s, despite having “materially lower expected revenue and earnings.”
Online sentiment on Stocktwits has shifted from bearish to neutral over the past 24 hours. Some users express concerns about the stock being overpriced, while others anticipate further gains due to “forced buying.”
Broader Market Context and Future Prospects
Looking at the broader market context, Moderna’s stock has gained a remarkable 596% year-to-date. It’s important to note that while the Nasdaq 100 inclusion is a milestone, it doesn’t guarantee future performance. Readers should remain informed and consider a wide range of factors when evaluating stocks in such indices. people watching Moderna stock are taking note.
In other market news, Strive’s Matt Cole predicts that Bitcoin could reach $500,000 by 2030, while Zscaler’s CEO has downplayed fears of AI disruption. Additionally, Rothschild has initiated coverage on AVAV, KTOS, and NOC stocks, noting changes in warfare and rising military spending. The Moderna stock market is responding.
In conclusion, Moderna’s re-entry into the Nasdaq-100 has been marked by a significant uptick in its share prices, largely buoyed by the promising results from its cancer vaccine trials. This development has captured the attention of many on platforms such as Stocktwits, where discussions around the company’s potential continue to flourish. While the cancer vaccine trial’s success has been a pivotal factor in the recent surge, it has also sparked conversations around potential valuation concerns. As Moderna navigates this dynamic landscape, the implications of its cancer vaccine advancements remain a focal point for many.
Why has Moderna rejoined the Nasdaq-100?
Moderna rejoined the Nasdaq-100 due to a significant recovery in its share price, which surged after the success of its late-stage trial results for a cancer vaccine in conjunction with Merck’s Keytruda. This boost in share performance allowed Moderna to replace Warner Bros. Discovery on the index. For further details, you can check the source here.
What impact does being included in the Nasdaq-100 have on Moderna?
Inclusion in the Nasdaq-100 often leads to index funds purchasing the stock around the effective date, though it does not directly alter Moderna’s sales or product pipeline. This change is mainly driven by market dynamics rather than fundamental business shifts. More information can be found here.
What are the concerns about Moderna’s current valuation?
Despite the positive momentum, there are concerns regarding Moderna’s valuation. Citi analyst Geoff Meacham downgraded the stock due to its market capitalisation being comparable to Regeneron’s, despite having lower expected revenue and earnings. This information is available in more detail here.
How has Moderna’s stock performed recently?
Moderna’s stock has seen a remarkable increase, trading at approximately $204 after a 7% rise from Friday’s close of $190.01. This marks a significant recovery from a 52-week low near $22 in November, climbing more than fivefold in 2026. Further reading is available here.
What role did the cancer vaccine trial play in Moderna’s recent success?
The successful late-stage trial of Moderna’s personalised cancer vaccine, developed in collaboration with Merck, was pivotal in the company’s share price recovery. The trial demonstrated that the vaccine, paired with Merck’s Keytruda, effectively delayed disease recurrence in high-risk melanoma patients. Additional context can be found here.
In other news: Stock Market News: US Futures Rise, Oil Prices Drop
